Celixir Appoints Eminent Cardiac Physician Scientist Professor Bernard Gersh to Scientific Advisory Board

Mayo Clinic Cardiology expert to support clinical development of innovative heart regeneration medicines 

Stratford-upon-Avon, UK, 2nd March 2020 – Celixir, a privately-owned company discovering and developing life-saving advanced therapies, today announces the appointment of Professor Bernard Gersh to Celixir’s Scientific Advisory Board.

Dr. Gersh is Professor of Medicine at the Mayo Clinic College of Medicine and Consultant in Cardiovascular Diseases and Internal Medicine, USA. His past positions include the W. Proctor Harvey Teaching Professor of Cardiology and Chief of the Division of Cardiology at Georgetown University Medical Center. Dr. Gersh received his MB, ChB, from the University of Cape Town in South Africa. He received his Doctor of Philosophy degree from Oxford University where he was a Rhodes Scholar.

Dr. Gersh’s wide interests include the natural history and therapy of acute and chronic coronary artery disease, clinical electrophysiology and in particular atrial fibrillation, sudden cardiac death and syncope, cardiac stem cell therapy, and the epidemiology of cardiovascular disease in the developing world. He has approximately 1195 publications (1047 manuscripts and 148 book chapters).

Ajan Reginald, Chief Executive Officer of Celixir, said“We are delighted to welcome Professor Bernie Gersh to Celixir’s Scientific Advisory Board as the lead independent cardiology advisor. Bernie is well recognised as a leading physician scientist and augments Celixir’s world-class panel of cardiac experts”.

Twitter Feed